CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 51 enrolled
Drug / intervention
TRPA1-inhibitor +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05275751
NCT05275751Early Ph 1Completed
CompareCT.gov

Human Heat Sensation - a Single-group, Randomized, Placebo-controlled, Adaptive, Full-factorial Crossover Trial

Medical University of Vienna·interventional·Posted Mar 11, 2022·Updated Mar 17, 2023

In Brief

A Early Phase 1 clinical trial evaluating TRPA1-inhibitor, TRPV1-inhibitor, and 3 other interventions for Pain. Completed, enrolled 51 participants across 1 site.

Detailed Summary

Animal studies suggest that the ion channels TRPV1, TRPA1 and TRPM3 are the relevant heat sensors. This study aims to validate these findings in humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesAustria
Collaborators--

Timeline

Early Ph 1CompletedFinished
2023202420252026
First PostedMar 11, 2022
Enrollment StartJun 13, 2022
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.3 years ago

Interventions

TRPA1-inhibitordrug

Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid

TRPV1-inhibitordrug

Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid

TRPM3-inhibitordrug

Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid

Placebodrug

No pharmacological intervention

Chloride-channel inhibitordrug

Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid